|
所在平台: Udemy |
课程主页: https://www.udemy.com/course/merger-and-acquisition-modelling/
课程评论：没有评论
课程名称：并购建模 课程概述：本课程是一门视频导向的强化课程，要求学员具备扎实的财务建模技巧以及对并购交易当前会计影响的认识。在课程中，学员将构建一个灵活的综合并购模型，用以分析拟议交易的临时信用比率和合并利润指标，同时还将设计识别最佳资本结构的功能，以用于融资收购。课程将贯穿应用最佳实践的财务建模和会计技术。 并购建模在会计和技术上面临与单一企业综合预测截然不同的挑战。本课程及所构建的模型适用于涉及并购交易发起或融资的股权、债务和信贷分析师，以及企业财务专家。课程中，我们将为日本武田制药收购Shire Pharmaceuticals的案例制作完整的预测，展示该交易中公允价值调整的巨大影响。 在课程结束时，学员将能够： - 从零开始建模一个并购，并更有效地填充和审查模板并购模型； - 模拟并购的各个方面，包括商誉和公允价值调整、再融资费用，并正确核算不同类型的合并调整、协同效应、无稀释协同效应，以及控制溢价； - 进行交易敏感性分析，并基于目标的临时信用指标建立最佳融资组合。
This intensive video-based course assumes a sound grasp of financial modelling techniques and awareness of the current accounting implications of M & A transactions.During the course, delegates will construct a flexible integrated merger model capable of analysing the pro-forma credit ratios and combined profit metrics of a proposed transaction whilst also building the functionality to identify the optimal capital structure to be used to finance an acquisition. Best practice financial modelling and accounting techniques will be applied throughout.Merger modelling presents a completely different accounting and technical challenge to preparing an integrated forecast for a single business. This course and the model built is relevant to both equity, debt and credit analysts and corporate financiers who are potentially involved in the origination of or financing of acquisitions.In the programme we will produce a complete forecast for the recent acquisition of Shire Pharmaceuticals by Takeda of Japan and see the huge impact of the fair value adjustments in this transaction.At the end of the programme delegates will:Be able to model a merger from scratch and more effectively populate and interrogate template merger models;Model all aspects of a merger including goodwill and fair value adjustments,refinancingfees and correctly accounting for the different types consolidation adjustmentssynergies, nil-dilution synergies and control premiadeal sensitivity and establishing an optimal financing mix based on target pro-forma credit metrics
